|
| | DECAMETHONIUM BROMIDE Basic information |
| Product Name: | DECAMETHONIUM BROMIDE | | Synonyms: | 1,10-Decanediaminium,N,N,N,N’,N’,N’-hexamethyl-,dibromide;10-decanediaminium,n,n,n,n’,n’,n’-hexamethyl-dibromide;decacuran;decamethoniumdibromide;decamethylene-1,10-bistrimethylammoniumdibromide;decamethylenebis(trimethyl-ammoniudibromide;1,10-Decanediaminium, N1,N1,N1,N10,N10,N10-hexamethyl-, bromide (1:2);dekamethoniumbromid | | CAS: | 541-22-0 | | MF: | C16H38Br2N2 | | MW: | 418.29 | | EINECS: | 208-772-2 | | Product Categories: | IMPROMEN;Ammonium Bromides (Quaternary);Quaternary Ammonium Compounds | | Mol File: | 541-22-0.mol |  |
| | DECAMETHONIUM BROMIDE Chemical Properties |
| Melting point | 263-267 °C(lit.) | | storage temp. | Inert atmosphere,Room Temperature | | solubility | DMF: 2 mg/ml; DMSO: 16 mg/ml; Ethanol: 33 mg/ml; PBS (pH 7.2): 5 mg/ml | | form | crystalline | | color | off-white | | Water Solubility | almost transparency | | λmax | λ: 240 nm Amax: 0.04
λ: 250 nm Amax: 0.03
λ: 260 nm Amax: 0.02
λ: 500 nm Amax: 0.02 | | Merck | 14,2847 | | BRN | 3728288 | | Stability: | Stable. Incompatible with strong oxidizing agents. | | CAS DataBase Reference | 541-22-0(CAS DataBase Reference) | | EPA Substance Registry System | Decamethonium dibromide (541-22-0) |
| Hazard Codes | T | | Risk Statements | 25-36/37/38 | | Safety Statements | 26-45 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | BP5950000 | | F | 3-10 | | HS Code | 2923.90.0100 | | HazardClass | 6.1(b) | | PackingGroup | III | | Toxicity | LD50 oral in mouse: 190mg/kg |
| | DECAMETHONIUM BROMIDE Usage And Synthesis |
| Description | Decamethonium is a depolarizing neuromuscular blocking agent. It is a partial agonist of muscle-type nicotinic acetylcholine receptors (nAChRs). Decamethonium activates α1β1-containing adult mouse muscle-type nAChRs expressed in X. laevis oocytes with an EC50 value of 40 μM using voltage clamp electrophysiology. It is also a nondepolarizing antagonist of neuronal-type nAChRs, inhibiting mouse α7-, α3β2-, α3β4-, and α4β2-containing receptors with IC50 values of 7.4, 405, 28, and 59 μM, respectively. Decamethonoium is a competitive antagonist of α4β2-containing nAChRs expressed in SH-EP1 cells (IC50 = 52 μM for the human receptor). It also inhibits electric eel acetylcholinesterase (AChE) and blocks electrically-evoked tibialis muscle twitches in anesthetized cats with ED95 values of 35 and 70 μg/kg for cats under chloralose and ether anesthesia, respectively. Formulations containing decamethonium have been used to induce paralysis during anesthesia. | | Chemical Properties | crystalline solid | | Uses | antipsychotic | | Brand name | Syncurine (GlaxoSmithKline). | | Biological Functions | Decamethonium was one of the first neuromuscular blocking agents to be synthesized. An SAR study on a series of bis-quaternary ammonium
compounds with varying numbers of methylene groups separating the nitrogen atoms demonstrated that maximal neuromuscular blockade
occurred with 10 to 12 unsubstituted methylene groups. Activity diminished as the number of carbons was either decreased or increased. The
compound with six methylene groups, hexamethonium, is a nicotinic antagonist at autonomic ganglia (ganglionic blocking agent). All the
compounds in this series that possessed neuromuscular blocking activity also caused depolarization of the postjunctional membrane. | | General Description | Crystals derived from methanol and acetone. | | Air & Water Reactions | Water soluble. | | Health Hazard | ACUTE/CHRONIC HAZARDS: When heated to decomposition DECAMETHONIUM BROMIDE emits very toxic fumes. | | Fire Hazard | Flash point data for DECAMETHONIUM BROMIDE are not available. DECAMETHONIUM BROMIDE is probably combustible. |
| | DECAMETHONIUM BROMIDE Preparation Products And Raw materials |
|
